Idenix SARL an MSD Company since August 2014

Montpellier, France

Idenix SARL an MSD Company since August 2014

Montpellier, France

Time filter

Source Type

Sizun G.,Idenix SARL an MSD Company since August 2014 | Pierra C.,Idenix SARL an MSD Company since August 2014 | Peyronnet J.,Idenix SARL an MSD Company since August 2014 | Badaroux E.,Idenix SARL an MSD Company since August 2014 | And 11 more authors.
Future Medicinal Chemistry | Year: 2015

Background: Ribonucleoside analogs possessing a β-methyl substituent at the 2′-position of the d-ribose moiety have been previously discovered to be potent and selective inhibitors of hepatitis C virus (HCV) replication, their triphosphates acting as alternative substrate inhibitors of the HCV RdRp NS5B. Results/methodology: In this article, the authors detail the synthesis, anti-HCV evaluation in cell-based replicon assays and structure-activity relationships of several phosphoramidate diester derivatives of 2′-C-methylguanosine (2′-MeG). Conclusion: The most promising compound, namely the O-[S-(hydroxyl)pivaloyl-2-thioethyl]{abbreviated as O-[(HO)tBuSATE)]} N-benzylamine phosphoramidate diester derivative (IDX184), was selected for further in vivo studies, and was the first clinical pronucleotide evaluated for the treatment of chronic hepatitis C up to Phase II trials. © 2015 Future Science Ltd.


PubMed | Idenix SARL an MSD Company since August 2014 and Idenix Pharmaceuticals
Type: Journal Article | Journal: Future medicinal chemistry | Year: 2015

Ribonucleoside analogs possessing a -methyl substituent at the 2-position of the d-ribose moiety have been previously discovered to be potent and selective inhibitors of hepatitis C virus (HCV) replication, their triphosphates acting as alternative substrate inhibitors of the HCV RdRp NS5B. Results/methodology: In this article, the authors detail the synthesis, anti-HCV evaluation in cell-based replicon assays and structure-activity relationships of several phosphoramidate diester derivatives of 2-C-methylguanosine (2-MeG).The most promising compound, namely the O-[S-(hydroxyl)pivaloyl-2-thioethyl]{abbreviated as O-[(HO)tBuSATE)]} N-benzylamine phosphoramidate diester derivative (IDX184), was selected for further in vivo studies, and was the first clinical pronucleotide evaluated for the treatment of chronic hepatitis C up to Phase II trials.

Loading Idenix SARL an MSD Company since August 2014 collaborators
Loading Idenix SARL an MSD Company since August 2014 collaborators